BioSpace News Archive

EyePoint Pharmaceuticals, Inc. announced that the American Medical Association Current Procedural Terminology Editorial Panel accepted the addition of a new Category III CPT code, 0X78T for the administration of a drug into the posterior chamber of the anterior segment of the eye, effective January 1, 2022, providing an opportunity for a reimbursement pathway for the administration of DEXYCU.

MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, announced key leadership appointments.

TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced Romain Attard has been appointed Chief Financial Officer of TISSIUM.

Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced new treatment guidelines for sarcoidosis from the European Respiratory Society (ERS), which include use of Acthar® Gel (repository corticotropin injection) therapy in the clinical management of certain patients with pulmonary sarcoidosis, published in European Respiratory Journal

Alterity Therapeutics has today announced the granting of a new composition of matter patent by the United States Patent and Trademark Office (USPTO).

Hart Medical Equipment, a leading durable medical equipment provider headquartered in Michigan is pleased to announce its merger with Northwest Ohio Medical Equipment, a division of Blanchard Valley Health System, in partnership with Wood County Hospital and The Bellevue Hospital.

Celularity Inc. and Arthrex, Inc. announced the companies have entered into an exclusive partnership to distribute and commercialize Celularity’s biomaterial products for orthopedic surgery and sports medicine.

Healthtech Solutions, Inc. (OTC: HLTT) (“Healthtech” or the “Company”), an innovative portfolio-model life sciences company focused on building impactful solutions for patients and the healthcare system through its subsidiary companies ranging in stage from pre-clinical to commercial growth, announced today that Brad Mathis was named Chief Operating Officer (COO) and Ryan Salomone was appointed to the Board of Directors.

Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced positive outcome from its preplanned interim futility analysis of its pivotal Phase 3 trial (ARMADA 2000) of CPI-613® (devimistat) for relapsed or refractory acute myeloid leukemia (AML) as determined by an independent Data Monitoring Committee (IDMC)

OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations.